SCHEMBL22700680

SCHEMBL22700680

O=C(Nc1cc(F)ccc1N1CCCCCC1)c1ccncc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRPK1 Q96SB4 2/20 0.74
KDR P35968 1/20 0.74
SRPK2 P78362 1/20 0.74
SRPK3 Q9UPE1 1/20 0.74
CDK4 P11802 1/20 0.74
CDK9 P50750 1/20 0.74
MAPT P10636 4/20 0.67
NPSR1 Q6W5P4 2/20 0.62
TDP1 Q9NUW8 1/20 0.62
ALDH1A1 P00352 5/20 0.61
RXFP1 Q9HBX9 1/20 0.61
POLB P06746 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
TSHR P16473 1/20 0.58
MAPK1 P28482 1/20 0.58
KMT2A Q03164 5/20 0.55
HPGD P15428 3/20 0.55
KDM4C Q9H3R0 1/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485720 1.00 SRPK1 (0.74) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL31187476 1.00 SRPK1 (0.74) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL20198520 0.87 NPSR1 (0.72) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL16697303 0.86 MAPT (0.64) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL1110476 0.85 SRPK1 (1.00) SRPK1KDRSRPK2SRPK3MAPT
SCHEMBL1110544 0.85 SRPK1 (1.00) SRPK1KDRSRPK2SRPK3MAPT
SCHEMBL3485927 0.85 SRPK1 (1.00) SRPK1KDRSRPK2SRPK3MAPT
SCHEMBL3485238 0.85 KDR (0.71) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL3485243 0.85 KDR (0.71) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL23196029 0.85 CDK4 (0.74) SRPK1KDRSRPK2SRPK3CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210100781-A1 TUMOR SUPPRESSION KYOTO UNIVERSITY (JP) 2021-04-08 US disclosed
WO-2020235672-A1 PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE 国立大学法人京都大学 (JP) 2020-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210100781-A1 TUMOR SUPPRESSION TSG101, TP53, VHL SRPK1 1293/4885KDR 3702/4885SRPK2 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.